164 related articles for article (PubMed ID: 36982528)
1. Exostosin 1 Knockdown Induces Chemoresistance in MV3 Melanoma Cells by Upregulating JNK and MEK/ERK Signaling.
Pfeifer V; Weber H; Wang Y; Schlesinger M; Gorzelanny C; Bendas G
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982528
[TBL] [Abstract][Full Text] [Related]
2. Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug Resistance.
Lanzi C; Zaffaroni N; Cassinelli G
Curr Med Chem; 2017; 24(26):2860-2886. PubMed ID: 28215163
[TBL] [Abstract][Full Text] [Related]
3. Pro-Angiogenic Effects of Latent Heparanase and Thrombin Receptor-Mediated Pathways-Do They Share a Common Ground in Melanoma Cells?
Hoß SG; Grundmann M; Benkel T; Gockel L; Schwarz S; Kostenis E; Schlesinger M; Ilan N; Vlodavsky I; Bendas G
Thromb Haemost; 2018 Oct; 118(10):1803-1814. PubMed ID: 30235481
[TBL] [Abstract][Full Text] [Related]
4. Latent heparanase facilitates VLA-4-mediated melanoma cell binding and emerges as a relevant target of heparin in the interference with metastatic progression.
Gerber U; Hoß SG; Shteingauz A; Jüngel E; Jakubzig B; Ilan N; Blaheta R; Schlesinger M; Vlodavsky I; Bendas G
Semin Thromb Hemost; 2015 Mar; 41(2):244-54. PubMed ID: 25682080
[TBL] [Abstract][Full Text] [Related]
5. Receptor tyrosine kinases and heparan sulfate proteoglycans: Interplay providing anticancer targeting strategies and new therapeutic opportunities.
Lanzi C; Cassinelli G
Biochem Pharmacol; 2020 Aug; 178():114084. PubMed ID: 32526230
[TBL] [Abstract][Full Text] [Related]
6. The exostosin glycosyltransferase 1/STAT3 axis is a driver of breast cancer aggressiveness.
Solaimuthu B; Khatib A; Tanna M; Karmi A; Hayashi A; Abu Rmaileh A; Lichtenstein M; Takoe S; Jolly MK; Shaul YD
Proc Natl Acad Sci U S A; 2024 Jan; 121(3):e2316733121. PubMed ID: 38215181
[TBL] [Abstract][Full Text] [Related]
7. Heparan sulfate proteoglycans and heparin regulate melanoma cell functions.
Nikitovic D; Mytilinaiou M; Berdiaki A; Karamanos NK; Tzanakakis GN
Biochim Biophys Acta; 2014 Aug; 1840(8):2471-81. PubMed ID: 24486410
[TBL] [Abstract][Full Text] [Related]
8. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
[TBL] [Abstract][Full Text] [Related]
9. The heparanase/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomas.
Cassinelli G; Zaffaroni N; Lanzi C
Cancer Lett; 2016 Nov; 382(2):245-254. PubMed ID: 27666777
[TBL] [Abstract][Full Text] [Related]
10. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
11. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
12. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
[TBL] [Abstract][Full Text] [Related]
13. Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived, heparin-binding synthetic peptide.
Drake SL; Klein DJ; Mickelson DJ; Oegema TR; Furcht LT; McCarthy JB
J Cell Biol; 1992 Jun; 117(6):1331-41. PubMed ID: 1607392
[TBL] [Abstract][Full Text] [Related]
14. Heparan sulfate proteoglycans mediate interstitial flow mechanotransduction regulating MMP-13 expression and cell motility via FAK-ERK in 3D collagen.
Shi ZD; Wang H; Tarbell JM
PLoS One; 2011 Jan; 6(1):e15956. PubMed ID: 21246051
[TBL] [Abstract][Full Text] [Related]
15. Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma.
Schrage YM; Hameetman L; Szuhai K; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
Am J Pathol; 2009 Mar; 174(3):979-88. PubMed ID: 19179614
[TBL] [Abstract][Full Text] [Related]
16. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies.
Sanderson RD; Yang Y; Kelly T; MacLeod V; Dai Y; Theus A
J Cell Biochem; 2005 Dec; 96(5):897-905. PubMed ID: 16149080
[TBL] [Abstract][Full Text] [Related]
17. Glycosyltransferases EXTL2 and EXTL3 cellular balance dictates heparan sulfate biosynthesis and shapes gastric cancer cell motility and invasion.
Marques C; Poças J; Gomes C; Faria-Ramos I; Reis CA; Vivès RR; Magalhães A
J Biol Chem; 2022 Nov; 298(11):102546. PubMed ID: 36181793
[TBL] [Abstract][Full Text] [Related]
18. Heparan Sulfate Proteoglycan Signaling in Tumor Microenvironment.
De Pasquale V; Pavone LM
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32916872
[TBL] [Abstract][Full Text] [Related]
19. An investigation of genetic polymorphisms in heparan sulfate proteoglycan core proteins and key modification enzymes in an Australian Caucasian multiple sclerosis population.
Okolicsanyi RK; Bluhm J; Miller C; Griffiths LR; Haupt LM
Hum Genomics; 2020 May; 14(1):18. PubMed ID: 32398079
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Heat Shock Transcription Factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel.
Vydra N; Toma A; Glowala-Kosinska M; Gogler-Piglowska A; Widlak W
BMC Cancer; 2013 Oct; 13():504. PubMed ID: 24165036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
